Found: 5
Select item for more details and to access through your institution.
Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant.
- Published in:
- European Journal of Clinical Pharmacology, 2022, v. 78, n. 4, p. 613, doi. 10.1007/s00228-022-03275-5
- By:
- Publication type:
- Article
Efficacy and safety of osimertinib in a Japanese compassionate use program.
- Published in:
- Japanese Journal of Clinical Oncology, 2017, v. 47, n. 7, p. 625, doi. 10.1093/jjco/hyx050
- By:
- Publication type:
- Article
Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight.
- Published in:
- Cancer Science, 2023, v. 114, n. 5, p. 2087, doi. 10.1111/cas.15736
- By:
- Publication type:
- Article
Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.770268
- By:
- Publication type:
- Article
Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.618570
- By:
- Publication type:
- Article